Wave Life Sciences, Inc. (WVE) has filed a post-effective amendment to its automatic shelf registration on Form S-3 to reflect its redomiciliation from Singapore to Delaware and related corporate changes, without registering any additional securities or paying new fees. All outstanding ordinary shares of the former Singapore parent were exchanged on a one-for-one basis for shares of Wave Life Sciences, Inc. common stock, and the Singapore entity became a subsidiary.
The amended base shelf allows the company, as a well-known seasoned issuer, to issue from time to time common stock, debt securities, warrants, rights and units, with specific terms to be set in future prospectus supplements. A related amended and restated open market sale agreement with Jefferies LLC provides for an at-the-market program of up to $250,000,000 of common stock; after prior sales of $101,381,538, capacity of up to $148,618,462 remains. Common stock is listed on The Nasdaq Global Market under the symbol WVE, with a last reported price of $5.74 on August 3, 2026.
Wave Life Sciences Ltd. reported a net loss of $69,355 thousand for the three months ended June 30, 2026, on collaboration revenue of $2,272 thousand, as operating expenses reached $76,074 thousand driven by $51,293 thousand in research and development and $24,781 thousand in general and administrative costs. For the first six months of 2026, revenue was $40,518 thousand and net loss was $95,442 thousand. Management stated that cash, cash equivalents and marketable securities of $490.6 million as of June 30, 2026 are expected to fund operations for at least twelve months.
The company remains a clinical‑stage RNA medicines developer with lead programs in obesity (WVE‑007), alpha‑1 antitrypsin deficiency (WVE‑006), PNPLA3 I148M liver disease (WVE‑008), Duchenne muscular dystrophy and Huntington’s disease, all built on its PRISM platform. Wave recognized $2,272 thousand of GSK collaboration revenue in the quarter and has about $22.6 million of deferred revenue remaining. It regained full rights to WVE‑006, advanced multiple clinical trials, and plans additional data readouts in 2026. Structural steps include a court‑approved redomiciliation from Singapore to Delaware expected in August 2026 and an extension of its Lexington, Massachusetts manufacturing lease, which increased operating lease right‑of‑use assets and liabilities by approximately $30.0 million.
Wave Life Sciences reported financial results for the quarter ended June 30, 2026. Revenue was $2,272 thousand and the net loss was $69,355 thousand, or $0.34 per basic and diluted share, as research and development plus general and administrative expenses totaled $76,074 thousand. For the first half of 2026, revenue reached $40,518 thousand with a net loss of $95,442 thousand.
The company highlighted progress across its RNA medicines pipeline. Dosing is underway in the Phase 2a multidose INLIGHT trial of obesity candidate WVE-007, and Phase 2 combination and post-incretin maintenance trials are described as on track to initiate in the second half of 2026. In alpha-1 antitrypsin deficiency, an FDA meeting is scheduled for the end of summer 2026 to discuss a potential accelerated approval pathway for RNA editing candidate WVE-006. A clinical trial application submission for liver disease program WVE-008 is described as on track for the second half of 2026. Management characterizes the company as well capitalized, citing $490.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, with an expected cash runway into the third quarter of 2028.
Wave Life Sciences Ltd. reported that its shareholders approved a court-supervised Scheme of Arrangement needed to complete the company’s redomiciliation. At a special meeting on June 22, 2026, 87 Scheme Shareholders voted, with all 87 voting in favor and none against.
These holders cast 155,190,836 shares for the Wave Redomiciliation Proposal and 78,429 shares against, for a total of 155,269,265 shares voted. The company will now apply to the Singapore High Court for approval of the Scheme of Arrangement and, if granted, expects the redomiciliation to take effect in mid‑2026.
Wave Life Sciences reported a positive update from its RestorAATion-2 Phase 1b/2a trial of WVE-006 for alpha-1 antitrypsin deficiency. WVE-006, a subcutaneous RNA editing therapy, reduced harmful Z-AAT protein and restored protective M-AAT to levels resembling low-risk MZ individuals with both biweekly and monthly dosing.
In the 200 mg biweekly cohort, total AAT reached 11.9 µM and M-AAT rose to 64.4% of total, while Z-AAT fell by 71%. A 400 mg monthly regimen produced similar effects, with 13.6 µM total AAT and strong Z-AAT reductions. Three acute infections triggered rapid AAT surges, showing restored dynamic protein production.
Editing effects were sustained for at least three months after the last dose, and WVE-006 was generally well tolerated with only mild to moderate adverse events and no serious events or liver test issues. Wave expects mid-2026 FDA feedback on a potential accelerated approval pathway and is hosting an investor webcast to discuss the data.
Wave Life Sciences Ltd. ownership disclosure: Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 1,000,000 Ordinary Shares, representing 0.53% of the class. The percentage is calculated using 188,254,954 Ordinary Shares outstanding as of February 19, 2026.
The filing states the shares are directly held by Adage Capital Partners, L.P., with shared voting and dispositive power reported by the named reporting persons. The business address for the reporting persons is 200 Clarendon Street, Boston, Massachusetts.
Wave Life Sciences Ltd. is asking shareholders to approve a redomiciliation that will make newly formed Wave Life Sciences, Inc., a Delaware corporation, the parent of the group. Each Wave-Singapore ordinary share will be exchanged on a one-for-one basis for Wave-Delaware common stock, which is expected to continue trading on Nasdaq under the symbol “WVE.”
The company cites closer alignment with its largely U.S.-based operations and shareholder base, as well as reduced duplicate regulatory, legal and reporting costs, as key reasons. A Singapore court–sanctioned Scheme of Arrangement requires approval by a majority in number of voting shareholders and at least 75% of shares voted at a June 22, 2026 special meeting in Cambridge, Massachusetts. Shareholders will not have appraisal rights under Singapore law, and the company intends that most holders will not recognize gain or loss for U.S. federal income tax purposes, though complex U.S., Singapore and U.K. tax consequences and potential changes in effective tax rate are highlighted as risks.
Wave Life Sciences Ltd reported that FMR LLC beneficially owns 5,192,761.43 shares of Common Stock, representing 2.8% of the class as reported on 03/31/2026. The filing states FMR LLC has sole voting power for 5,189,539 shares and sole dispositive power for 5,192,761.43 shares. The filing also notes that Abigail P. Johnson is reported with dispositive power over the same 5,192,761.43 shares. The schedule includes a statement that one or more other persons are known to have rights to dividends or sale proceeds, none exceeding 5%.
Wave Life Sciences Ltd. proposes to redomicile its parent from Singapore to Delaware via a Scheme of Arrangement. Under the plan, each issued Wave-Singapore ordinary share will be exchanged one-for-one for a newly issued share of Wave Life Sciences, Inc. (Wave-Delaware) common stock, which the company intends to list on Nasdaq under the symbol WVE. The Scheme requires shareholder approval at a Special Meeting convened by the Singapore Court and subsequent court sanction; it also remains subject to other Implementation Agreement conditions and a Long-Stop Date. The Board unanimously recommends a "FOR" vote. The proxy statement describes differences between Singapore and Delaware governance, potential tax (including Singapore stamp duty at 0.2%) and accounting treatment (common-control reorganization under U.S. GAAP), and implementation mechanics for equity awards, pre-funded warrants and transfer procedures.
Wave Life Sciences Ltd. filed an amendment to its annual report to provide detailed Part III information on directors, executive officers, governance and executive compensation for the year ended December 31, 2025. The company highlights a nine‑member board, fully independent key committees, and strong say‑on‑pay support.
The amendment describes 2025 business milestones across obesity, genetic liver and neuromuscular programs, a major collaboration with GSK, and a December 2025 equity financing that raised approximately $402.5 million, ending the year with $602.1 million in cash and cash equivalents. It also explains performance‑based cash bonuses, multi‑year option and RSU grants, and severance and change‑of‑control protections for senior leaders.